WO2007014927A2 - Inhibiteurs macrocycliques du virus de l'hepatite c - Google Patents

Inhibiteurs macrocycliques du virus de l'hepatite c Download PDF

Info

Publication number
WO2007014927A2
WO2007014927A2 PCT/EP2006/064822 EP2006064822W WO2007014927A2 WO 2007014927 A2 WO2007014927 A2 WO 2007014927A2 EP 2006064822 W EP2006064822 W EP 2006064822W WO 2007014927 A2 WO2007014927 A2 WO 2007014927A2
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
methyl
formula
alkyl
compound
Prior art date
Application number
PCT/EP2006/064822
Other languages
English (en)
Other versions
WO2007014927A3 (fr
Inventor
Pierre Jean-Marie Bernard Raboisson
Herman Augustinus De Kock
Lili Hu
Kenneth Alan Simmen
Karin Charlotta Lindquist
Mats Stefan LINDSTRÖM
Anna Karin Gertrud Linnea Belfrage
Horst Jürgen WÄHLING
Karl Magnus Nilsson
Bengt Bertil Samuelsson
Åsa Annica Kristina ROSENQUIST
Sven Crister Sahlberg
Hans Kristian Wallberg
Pia Cecilia Kahnberg
Björn Olof CLASSON
Original Assignee
Tibotec Pharmaceuticals Ltd.
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007014927(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP06764268A priority Critical patent/EP1912981B1/fr
Priority to RSP-2010/0183A priority patent/RS51227B/sr
Priority to NZ564540A priority patent/NZ564540A/en
Priority to PL06764268T priority patent/PL1912981T3/pl
Priority to DE602006011905T priority patent/DE602006011905D1/de
Priority to JP2008523383A priority patent/JP5230418B2/ja
Priority to AT06764268T priority patent/ATE455775T1/de
Priority to MEP-2012-119A priority patent/ME01454B/me
Priority to CA2617103A priority patent/CA2617103C/fr
Priority to EA200800482A priority patent/EA014188B1/ru
Priority to US11/995,900 priority patent/US7659245B2/en
Priority to AU2006274866A priority patent/AU2006274866B2/en
Priority to BRPI0614153-6A priority patent/BRPI0614153A2/pt
Priority to DK06764268.6T priority patent/DK1912981T3/da
Priority to KR1020087004894A priority patent/KR101083631B1/ko
Priority to CN2006800278839A priority patent/CN101233131B/zh
Application filed by Tibotec Pharmaceuticals Ltd., Medivir Ab filed Critical Tibotec Pharmaceuticals Ltd.
Publication of WO2007014927A2 publication Critical patent/WO2007014927A2/fr
Publication of WO2007014927A3 publication Critical patent/WO2007014927A3/fr
Priority to IL188320A priority patent/IL188320A/en
Priority to NO20081075A priority patent/NO20081075L/no
Priority to HK08106903.5A priority patent/HK1116488A1/xx
Priority to HR20100209T priority patent/HRP20100209T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Abstract

L'invention concerne des composés de formule (I) et des N-oxydes, sels, et stéréoisomères de ceux-ci. Dans ladite formule : A représente OR1, NHS(=O)PR2 ; R1 représentant hydrogène, C1-C6 alkyle, C0-C3 alkylènecarbocyclyle, C0-C3 alkylènehétérocyclyle ; R2 représentant C1-C6 alkyle, C0-C3 alkylènecarbocyclyle, C0-C3 alkylènehétérocyclyle ; p valant indépendamment 1 ou 2 ; n valant 3, 4, 5 ou 6; ---- représentant une double liaison facultative; L représente N ou CRz ; Rz représentant H ou formant une double liaison avec le carbone marqué par un astérisque ; Rq représente H ou, lorsque L représente CRz, Rq peut également représenter C1-C6 alkyle ; Rr représente quinazolinyle, éventuellement substitué par deux ou trois substituants chacun indépendamment sélectionné parmi C1-C6 alkyle, C1-C6 alcoxy, hydroxyle, halo, halo C1-C6 alkyle, amino, mono- ou dialkylamino, mono- ou dialkylaminocarbonyle, C1-C6 alkyl-carbonylamino, C0-C3 alkylènecarbocyclyle et C0-C3 alkylènehétérocyclyle ; R5 représente hydrogène, C1-C6alkyle, C1-C6 alcoxy, C1-C6 alkyle ou C3-C7 cycloalkyle ; R6 représente hydrogène, C1-C6 alkyle, C1-C6 alcoxy, C0-C3 alkylènecarbocyclyle, C0-C3 alkylènehétérocyclyle, hydroxy, bromo, chloro ou fluoro. Lesdits composés sont utiles dans le traitement ou la prophylaxie d'infections flavivirales de type virus de l'hépatite C.
PCT/EP2006/064822 2005-07-29 2006-07-28 Inhibiteurs macrocycliques du virus de l'hepatite c WO2007014927A2 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
RSP-2010/0183A RS51227B (sr) 2005-07-29 2006-07-28 Makrociklički inhibitori virusa hepatitisa c
AU2006274866A AU2006274866B2 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis C virus
US11/995,900 US7659245B2 (en) 2005-07-29 2006-07-28 Macrocylic inhibitors of hepatitis C virus
PL06764268T PL1912981T3 (pl) 2005-07-29 2006-07-28 Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
DE602006011905T DE602006011905D1 (de) 2005-07-29 2006-07-28 Makrocyclische inhibitoren des hepatitis-c-virus
JP2008523383A JP5230418B2 (ja) 2005-07-29 2006-07-28 Ｃ型肝炎ウイルスの大員環式阻害剤
AT06764268T ATE455775T1 (de) 2005-07-29 2006-07-28 Makrocyclische inhibitoren des hepatitis-c-virus
MEP-2012-119A ME01454B (me) 2005-07-29 2006-07-28 Makrociklički inhibitori virusa hepatitisa e
CA2617103A CA2617103C (fr) 2005-07-29 2006-07-28 Inhibiteurs macrocycliques du virus de l'hepatite c
BRPI0614153-6A BRPI0614153A2 (pt) 2005-07-29 2006-07-28 inibidores macrocìclicos do vìrus da hepatite c e composição farmacêutica que os contém
NZ564540A NZ564540A (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis C virus
EP06764268A EP1912981B1 (fr) 2005-07-29 2006-07-28 Inhibiteurs macrocycliques du virus de l'hepatite c
EA200800482A EA014188B1 (ru) 2005-07-29 2006-07-28 Макроциклические ингибиторы вируса гепатита с
DK06764268.6T DK1912981T3 (da) 2005-07-29 2006-07-28 Makrocykliske inhibitorer af Hepatitis C-virus
KR1020087004894A KR101083631B1 (ko) 2005-07-29 2006-07-28 Ｃ형 간염 바이러스의 마크로사이클릭 억제제
CN2006800278839A CN101233131B (zh) 2005-07-29 2006-07-28 丙型肝炎病毒的大环抑制剂
IL188320A IL188320A (en) 2005-07-29 2007-12-20 Macrocyclic inhibitors of the hepatitis c virus, pharmaceutical preparations that include them and their production
NO20081075A NO20081075L (no) 2005-07-29 2008-02-29 Macrocykliske inhibitorer av hepatitt C virus
HK08106903.5A HK1116488A1 (en) 2005-07-29 2008-06-20 Macrocyclic inhibitors of hepatitis c virus
HR20100209T HRP20100209T1 (hr) 2005-07-29 2010-04-14 Makrociklički inhibitori virusa hepatitisa c

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05107057.1 2005-07-29
EP05107057 2005-07-29
EP06113097 2006-04-25
EP06113097.7 2006-04-25

Publications (2)

Publication Number Publication Date
WO2007014927A2 true WO2007014927A2 (fr) 2007-02-08
WO2007014927A3 WO2007014927A3 (fr) 2007-11-29

Family

ID=37708968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/064822 WO2007014927A2 (fr) 2005-07-29 2006-07-28 Inhibiteurs macrocycliques du virus de l'hepatite c

Country Status (32)

Country Link
US (1) US7659245B2 (fr)
EP (1) EP1912981B1 (fr)
JP (1) JP5230418B2 (fr)
KR (1) KR101083631B1 (fr)
AP (1) AP2585A (fr)
AR (1) AR057702A1 (fr)
AT (1) ATE455775T1 (fr)
AU (1) AU2006274866B2 (fr)
BR (1) BRPI0614153A2 (fr)
CA (1) CA2617103C (fr)
CY (1) CY1110008T1 (fr)
DE (1) DE602006011905D1 (fr)
DK (1) DK1912981T3 (fr)
EA (1) EA014188B1 (fr)
ES (1) ES2339702T3 (fr)
GT (1) GT200600343A (fr)
HK (1) HK1116488A1 (fr)
HR (1) HRP20100209T1 (fr)
IL (1) IL188320A (fr)
ME (1) ME01454B (fr)
MY (1) MY151026A (fr)
NO (1) NO20081075L (fr)
NZ (1) NZ564540A (fr)
PE (1) PE20070343A1 (fr)
PL (1) PL1912981T3 (fr)
PT (1) PT1912981E (fr)
RS (1) RS51227B (fr)
SI (1) SI1912981T1 (fr)
SV (1) SV2008002641A (fr)
TW (1) TWI387597B (fr)
UY (1) UY29704A1 (fr)
WO (1) WO2007014927A2 (fr)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090149491A1 (en) * 2007-11-13 2009-06-11 Dong Liu Carbocyclic oxime hepatitis c virus serine protease inhibitors
WO2009084695A1 (fr) 2007-12-28 2009-07-09 Carna Biosciences Inc. Dérivé de 2-aminoquinazoline
US7608590B2 (en) 2004-01-30 2009-10-27 Medivir Ab HCV NS-3 serine protease inhibitors
JP2010510192A (ja) * 2006-11-17 2010-04-02 テイボテク・フアーマシユーチカルズ・リミテツド Ｃ型肝炎ウイルスの大環状阻害剤
US20100113440A1 (en) * 2007-02-08 2010-05-06 Tibotec Pharmaceuticals, Ltd. Pyrimidine substituted macrocyclic hcv inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7781474B2 (en) 2006-07-05 2010-08-24 Intermune, Inc. Inhibitors of hepatitis C virus replication
JP2010535173A (ja) * 2007-08-03 2010-11-18 コスモ・ソチエタ・ペル・アチオニ コルテキソロンの１７α−モノエステルおよび／またはその９，１１−デヒドロ誘導体を得るための酵素的方法
JP2010540549A (ja) * 2007-09-24 2010-12-24 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製阻害剤としての尿素含有ペプチド
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7915291B2 (en) 2002-05-20 2011-03-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US8148399B2 (en) 2005-07-29 2012-04-03 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
EP2435419A1 (fr) * 2009-05-29 2012-04-04 Syngenta Participations AG Quinazolines substituées, utilisées en tant que fongicides
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8183277B2 (en) 2005-07-29 2012-05-22 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis C virus
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8227407B2 (en) 2005-07-29 2012-07-24 Medivir Ab Macrocyclic inhibitors of hepatitis C virus
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US8372802B2 (en) 2008-03-20 2013-02-12 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8614180B2 (en) 2008-12-10 2013-12-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8785378B2 (en) 2006-07-13 2014-07-22 Achillion Pharmaceuticals, Inc. Macrocyclic peptides as inhibitors of viral replication
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
US9126986B2 (en) 2011-12-28 2015-09-08 Janssen Sciences Ireland Uc Hetero-bicyclic derivatives as HCV inhibitors
US9321758B2 (en) 2009-02-27 2016-04-26 Janssen Pharmaceuticals, Inc. Amorphous salt of a macrocyclic inhibitor of HCV
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10603327B2 (en) 2015-06-22 2020-03-31 Cassiopea S.P.A. High concentration formulation

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PT2121674E (pt) * 2007-02-01 2010-09-03 Tibotec Pharm Ltd Processos e intermediários para a preparação de um inibidor macrocíclico da protease do hcv
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
AU2011352145A1 (en) 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
WO2012109398A1 (fr) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
NZ707115A (en) * 2012-10-15 2018-03-23 Albemarle Corp Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds
EP3089757A1 (fr) 2014-01-03 2016-11-09 AbbVie Inc. Formes galéniques antivirales solides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053349A2 (fr) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Inhibiteurs de virus de l'hepatite c
WO2004037855A1 (fr) * 2002-10-25 2004-05-06 Boehringer Ingelheim International Gmbh Peptides macrocycliques actifs contre le virus de l'hepatite c
WO2005028501A1 (fr) * 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Peptides macrocycliques actifs contre le virus de l'hepatite c

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
NZ561851A (en) 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
KR100940619B1 (ko) * 2003-02-07 2010-02-05 이난타 파마슈티칼스, 인코포레이티드 마크로사이클릭 씨형 간염 세린 단백효소 억제제
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
AR048401A1 (es) * 2004-01-30 2006-04-26 Medivir Ab Inhibidores de la serina-proteasa ns3 del vhc
RU2419619C2 (ru) * 2005-07-29 2011-05-27 Медивир Аб Макроциклические ингибиторы вируса гепатита с
CN101273030B (zh) * 2005-07-29 2012-07-18 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN101273042B (zh) * 2005-07-29 2013-11-06 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053349A2 (fr) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Inhibiteurs de virus de l'hepatite c
WO2004037855A1 (fr) * 2002-10-25 2004-05-06 Boehringer Ingelheim International Gmbh Peptides macrocycliques actifs contre le virus de l'hepatite c
WO2005028501A1 (fr) * 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Peptides macrocycliques actifs contre le virus de l'hepatite c

Cited By (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636375B2 (en) 2002-05-20 2017-05-02 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8299094B2 (en) 2002-05-20 2012-10-30 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7915291B2 (en) 2002-05-20 2011-03-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10172846B2 (en) 2004-01-30 2019-01-08 Medivir Ab HCV NS-3 serine protease inhibitors
US7608590B2 (en) 2004-01-30 2009-10-27 Medivir Ab HCV NS-3 serine protease inhibitors
US7671032B2 (en) 2004-01-30 2010-03-02 Medivir Ab HCV NS-3 serine protease inhibitors
US9353103B2 (en) 2005-07-29 2016-05-31 Janssen Sciences Ireland Uc Macrocyclic inhibitors of hepatitis C virus
US8349869B2 (en) 2005-07-29 2013-01-08 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis C virus
US8754116B2 (en) 2005-07-29 2014-06-17 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis C virus
US9856265B2 (en) 2005-07-29 2018-01-02 Janssen Sciences Ireland Uc Macrocyclic inhibitors of hepatitis C virus
US8183277B2 (en) 2005-07-29 2012-05-22 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis C virus
US8754106B2 (en) 2005-07-29 2014-06-17 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis C virus
US9040562B2 (en) 2005-07-29 2015-05-26 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis C virus
US8153800B2 (en) 2005-07-29 2012-04-10 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
US9623022B2 (en) 2005-07-29 2017-04-18 Janssen Sciences Ireland Uc Macrocyclic inhibitors of hepatitis C virus
US8741926B2 (en) 2005-07-29 2014-06-03 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis C virus
US8148399B2 (en) 2005-07-29 2012-04-03 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
US8227407B2 (en) 2005-07-29 2012-07-24 Medivir Ab Macrocyclic inhibitors of hepatitis C virus
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7781474B2 (en) 2006-07-05 2010-08-24 Intermune, Inc. Inhibitors of hepatitis C virus replication
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9610317B2 (en) 2006-07-13 2017-04-04 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US9233136B2 (en) 2006-07-13 2016-01-12 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8785378B2 (en) 2006-07-13 2014-07-22 Achillion Pharmaceuticals, Inc. Macrocyclic peptides as inhibitors of viral replication
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2014221756A (ja) * 2006-11-17 2014-11-27 ヤンセン・アールアンドデイ・アイルランド Ｃ型肝炎ウイルスの大環状阻害剤
JP2010510192A (ja) * 2006-11-17 2010-04-02 テイボテク・フアーマシユーチカルズ・リミテツド Ｃ型肝炎ウイルスの大環状阻害剤
US8937080B2 (en) * 2007-02-08 2015-01-20 Medivir Ab Pyrimidine substituted macrocyclic HCV inhibitors
US20100113440A1 (en) * 2007-02-08 2010-05-06 Tibotec Pharmaceuticals, Ltd. Pyrimidine substituted macrocyclic hcv inhibitors
US9433628B2 (en) 2007-08-03 2016-09-06 Cassiopea Spa Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US11938141B2 (en) 2007-08-03 2024-03-26 Cassiopea S.P.A. Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US11207332B2 (en) 2007-08-03 2021-12-28 Cassiopea S.P.A. Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US10716796B2 (en) 2007-08-03 2020-07-21 Cassiopea S.P.A. Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US10166245B2 (en) 2007-08-03 2019-01-01 Cassiopea S.P.A. Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US10159682B2 (en) 2007-08-03 2018-12-25 Cassiopea S.P.A. Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
JP2010535173A (ja) * 2007-08-03 2010-11-18 コスモ・ソチエタ・ペル・アチオニ コルテキソロンの１７α−モノエステルおよび／またはその９，１１−デヒドロ誘導体を得るための酵素的方法
US8785427B2 (en) 2007-08-03 2014-07-22 Cosmo Dermatos Srl Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
US9486458B2 (en) 2007-08-03 2016-11-08 Cassiopea Spa Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
JP2010540549A (ja) * 2007-09-24 2010-12-24 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製阻害剤としての尿素含有ペプチド
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US20090149491A1 (en) * 2007-11-13 2009-06-11 Dong Liu Carbocyclic oxime hepatitis c virus serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
US8338606B2 (en) 2007-12-21 2012-12-25 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2009084695A1 (fr) 2007-12-28 2009-07-09 Carna Biosciences Inc. Dérivé de 2-aminoquinazoline
US8372802B2 (en) 2008-03-20 2013-02-12 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8357806B2 (en) 2008-09-04 2013-01-22 Bristol-Myers Squibb Company Process for synthesizing substituted isoquinolines
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8877929B2 (en) 2008-09-04 2014-11-04 Bristol-Myers Squibb Company Process for synthesizing substituted isoquinolines
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9133115B2 (en) 2008-12-10 2015-09-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8614180B2 (en) 2008-12-10 2013-12-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9321758B2 (en) 2009-02-27 2016-04-26 Janssen Pharmaceuticals, Inc. Amorphous salt of a macrocyclic inhibitor of HCV
EP2435419A1 (fr) * 2009-05-29 2012-04-04 Syngenta Participations AG Quinazolines substituées, utilisées en tant que fongicides
US9527885B2 (en) 2011-05-05 2016-12-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9126986B2 (en) 2011-12-28 2015-09-08 Janssen Sciences Ireland Uc Hetero-bicyclic derivatives as HCV inhibitors
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US10603327B2 (en) 2015-06-22 2020-03-31 Cassiopea S.P.A. High concentration formulation
US10980819B2 (en) 2015-06-22 2021-04-20 Cassiopea S.P.A. High concentration formulation
US11213531B2 (en) 2015-06-22 2022-01-04 Cassiopea S.P.A. High concentration formulation
US11883415B2 (en) 2015-06-22 2024-01-30 Cassiopea S.P.A. High concentration formulation

Also Published As

Publication number Publication date
UY29704A1 (es) 2007-05-31
CY1110008T1 (el) 2015-01-14
PT1912981E (pt) 2010-04-16
EP1912981A2 (fr) 2008-04-23
JP5230418B2 (ja) 2013-07-10
DE602006011905D1 (de) 2010-03-11
EA200800482A1 (ru) 2008-06-30
KR20080033475A (ko) 2008-04-16
WO2007014927A3 (fr) 2007-11-29
TW200745116A (en) 2007-12-16
SI1912981T1 (sl) 2010-05-31
EP1912981B1 (fr) 2010-01-20
NO20081075L (no) 2008-04-25
DK1912981T3 (da) 2010-05-25
IL188320A0 (en) 2008-04-13
PE20070343A1 (es) 2007-05-12
TWI387597B (zh) 2013-03-01
US7659245B2 (en) 2010-02-09
GT200600343A (es) 2007-08-06
AU2006274866B2 (en) 2012-04-12
AR057702A1 (es) 2007-12-12
NZ564540A (en) 2010-03-26
AP2585A (en) 2013-02-04
IL188320A (en) 2014-07-31
SV2008002641A (es) 2008-07-23
CA2617103A1 (fr) 2007-02-08
ATE455775T1 (de) 2010-02-15
ME01454B (me) 2014-04-20
JP2009502890A (ja) 2009-01-29
US20090118312A1 (en) 2009-05-07
CA2617103C (fr) 2015-01-06
HRP20100209T1 (hr) 2010-05-31
EA014188B1 (ru) 2010-10-29
BRPI0614153A2 (pt) 2011-03-15
MY151026A (en) 2014-03-31
PL1912981T3 (pl) 2010-07-30
KR101083631B1 (ko) 2011-11-16
HK1116488A1 (en) 2008-12-24
RS51227B (sr) 2010-12-31
ES2339702T3 (es) 2010-05-24
AU2006274866A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
AU2006274866B2 (en) Macrocyclic inhibitors of hepatitis C virus
US7700552B2 (en) Macrocyclic inhibitors of hepatitis C virus
RU2441870C2 (ru) Макроциклические ингибиторы вируса гепатита с
KR101381176B1 (ko) Ｃ형 간염 바이러스의 마크로사이클릭 억제제
BRPI0614654B1 (pt) Inibidores macrocíclicos de vírus de hepatite c
EP1912997A1 (fr) Inhibiteurs macrocycliques du virus de l'hépatite c
CA2677697A1 (fr) Inhibiteurs macrocycliques du virus de l'hepatite c (vhc) substitues par pyrimidine
WO2007014921A1 (fr) Inhibiteurs macrocycliques du virus de l'hépatite c
EP1912995A1 (fr) Inhibiteurs macrocycliques du virus de l'hépatite c
MX2008001393A (en) Macrocyclic inhibitors of hepatitis c virus

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006764268

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 564540

Country of ref document: NZ

Ref document number: 1200702725

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 188320

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006274866

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: AP/P/2008/004306

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 11995900

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 631/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008010149

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/001393

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008523383

Country of ref document: JP

Ref document number: 2617103

Country of ref document: CA

Ref document number: 200680027883.9

Country of ref document: CN

Ref document number: 12008500256

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006274866

Country of ref document: AU

Date of ref document: 20060728

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006274866

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087004894

Country of ref document: KR

Ref document number: 200800482

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06764268

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006764268

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P-2010/0183

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0614153

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080129